Maraviroc Switch Vascular Endothelium (VE) Substudy: a Substudy of MARCH [SUBSTUDY OF 700201758]
Phase of Trial: Phase IV
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Maraviroc (Primary) ; HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms MARCH-VE
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 May 2013 Planned end date changed from 1 Feb 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.